Veradermics' VDPHL01 hair loss pill aces Phase III trial

Veradermics reported positive results from a randomized, placebo-controlled Phase III trial of VDPHL01, an extended-release oral minoxidil formulation. 55% of once-daily and 68% of twice-daily users reported improved hair coverage versus 15% on placebo, with no serious or cardiac-related adverse events.

• 55% once-daily and 68% twice-daily users saw improved hair coverage vs 15% on placebo
• Trial enrolled roughly 500 men with mild to moderate pattern hair loss
• Hypertrichosis occurred in up to 9% of users; under 1% discontinued over side effects
• Company cites Nutrafol at about $90 a month as a price benchmark